How do MedTech manufacturers accelerate product development through structured prototyping without breaching documentation obligations within the design controls process?

Structured prototyping differs from informal tinkering through sequence: first the evaluation objective, then the prototype. A prototype without a predefined acceptance criterion answers no design question; it merely produces an object. By contrast, those who define for each phase which prototype type is to resolve which open question against which criterion turn every iteration into usable evidence. The results belong directly in the Design History File under 21 CFR 820.30 and support the design and development evidence under ISO 13485:2016 Section 7.3, not as a retrospective collection, but as ongoing documentation that captures design decisions at the moment they are justified.

The real hurdle lies not in the manufacturing technology, but in the timing of design freeze. Every design question left open before the freeze becomes a change afterwards that triggers renewed verification and, where applicable, a renewed risk assessment under ISO 14971. That is why we shift the effort forward: into more and more targeted iterations that feed risks and usability findings under IEC 62366-1 back into the risk analysis and the design before verification begins. In this way, design freeze becomes the confirmation of a mature design rather than the start of an expensive correction loop.